

*Editorial****Drosophila* models of cancer****Helena E. Richardson**<sup>1,2,3,4, \*</sup>

<sup>1</sup> Cell Cycle and Development Laboratory, Research Division, Peter MacCallum Cancer Centre, 7 St Andrew's place, East Melbourne, Melbourne, Victoria, 3002, Australia</br>

<sup>2</sup> Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, 7 St Andrew's place, East Melbourne, Melbourne, Victoria, 3002, Australia</br>

<sup>3</sup> Department of Anatomy and Neuroscience, University of Melbourne, 1-100 Grattan street, Parkville, Melbourne, Victoria, 3010, Australia</br>

<sup>4</sup> Department of Biochemistry and Molecular Biology, University of Melbourne, 1-100 Grattan street, Parkville, Melbourne, Victoria, 3010, Australia</br>

**Correspondence:** Email: [helena.richardson@petermac.org](mailto:helena.richardson@petermac.org)

---

In this special edition of *AIMS Genetics*, we highlight the use of the genetically amenable vinegar fly, *Drosophila melanogaster*, in modeling cancer. *Drosophila* has been an important model organism for over 100 years, and has made major contributions to the discipline of cell and developmental biology by the discovery of new genes and signaling pathways. Furthermore, research using *Drosophila* has provided seminal insights into gene function, which are relevant to human health. After the sequencing of the *Drosophila* and human genomes, it has become apparent that ~ 70% of human disease genes are conserved in *Drosophila* [1]. In recent years, *Drosophila* is being used more frequently as a model for many human diseases, including cancer [2-6]. *Drosophila* presents many advantages as an *in vivo* model system for the study of cellular processes that contribute to human cancer, including the evolutionary conservation of *Drosophila* genes with mammalian genes, its lower genetic redundancy, genetic manipulability, short life cycle, easy maintenance and low research costs. In regard to the hallmarks of human cancer [7], *Drosophila* presents a suitable model for the majority of these cancer hallmarks, including continued cell proliferation, resistance to apoptosis, impaired differentiation, altered metabolism, defective innate immune response, altered cell morphology and invasion/metastasis [2,6,8-12]. Additionally, aberrant asymmetric cell division and differentiation of stem cells are contributing factors in at least some human cancers [13,14,15]. In this regard, *Drosophila* presents several systems where the interaction of genetically altered stem cells with their niche in tumorigenesis can be studied [11,16-24]. In this special edition, we present eight reviews that highlight the various ways in which *Drosophila* has been used to understand the hallmarks of cancer. In particular, these reviews cover how *Drosophila* models have revealed the involvements of signaling

---

pathways in tissue growth and tumorigenesis [25,26,27], how altered cell polarity or differentiation contributes to stem cell induced tumorigenesis [28,29], the understanding of invasion/metastasis mechanisms [30], cell-competition and non-cell autonomous aspects of tumorigenesis [31] and the impact of chromosome instability on tumor progression [32]. Moreover, these reviews highlight different *Drosophila* systems that are used to model cancer; epithelial tissues [25,26,27,30,31,32], neural stem cells [28] and germ-line stem cells [29].

Signaling pathway perturbations have a powerful impact on the process of tumorigenesis because of the multiple targets that they control, however whether they promote or inhibit tumor growth or invasion/metastasis can be context dependent. The Notch signaling pathway, which was discovered via *Drosophila* genetics studies ~ 100 years ago, is a cell-cell interaction signaling pathway involved in tissue growth control and cell fate decisions and plays a context-dependent role in tumorigenesis [33,34]. In this special issue, Antonio Boanza and colleague highlight the function of Notch signaling during *Drosophila* development and how its deregulation leads to tumorigenesis [27].

The Hippo negative growth control pathway is a conserved signaling pathway, initially discovered in *Drosophila* [35]. The deactivation of this pathway affects the expression of cell growth, proliferation and survival genes. There is accumulating evidence that deregulation of the Hippo pathway is a major player in many human cancers [36,37]. Recently, *Drosophila* studies have revealed cross-talk between the Hippo pathway and the Jun-kinase (JNK) stress response pathway, which shows context dependent effects in human cancer [38]. In this special edition, Xianjue Ma reviews the importance of the Hippo and JNK pathways, and their interactions in tissue growth and invasion/metastasis in *Drosophila* models of tumorigenesis [26].

The transcription factor and oncogene, Myc, is a central player in tissue growth control that is controlled by the Hippo and Notch pathways, as well as several other signaling pathways in *Drosophila* [39,40,41]. In this special edition, Leonie Quinn and colleagues review how research in *Drosophila* has provided insights into the regulation and function of Myc and how these studies relate to the role of Myc in human cancer [25]. Myc is also a key factor in cell competition, which is a cell surveillance mechanism that enables the detection of less-fit cells. Cell competition was initially discovered in *Drosophila*, but also has relevance to mammalian tissue homeostasis and cancer [39,41,42,43]. The removal of unfit cells involves interaction of the *Drosophila* macrophage-like cells (hemocytes), which are the cellular component of the innate immune system [8,9]. Studies in *Drosophila* have also revealed that in the repair of damaged tissue, dying cells induce compensatory proliferation of surrounding cells, which is also likely to be relevant in the response of human tumors to chemotherapy [44,45]. In this special edition, Tin Tin Su reviews how the analysis of cell-cell interactions and whole organism responses to tissue damage or genetically aberrant cells in *Drosophila* has contributed to our understanding of the interaction of a tumor with its microenvironment in human cancer [31]. Since the tumor microenvironment is emerging as a major factor in the aetiology of mammalian cancer progression [7,46-49], these studies in *Drosophila* provide new insights into the understanding of human cancer.

Stem cells play an important role in several human cancers, where altered stem cell division regulation and/or differentiation programs contribute to tumor overgrowth [13,14,15]. Two reviews in this special issue cover the important topic of stem cells in cancer in different *Drosophila* tissues [28,29]. Louise Cheng and colleagues review the literature on *Drosophila* neural stem cells and how this work is providing insight into human brain cancer [28]. Greg Somers and colleague review the germ-line stem cells of the *Drosophila* testes and ovaries and how this research is contributing to

our understanding of stem cell—somatic cell niche interactions that are relevant to human cancer [29]. These reviews highlight the importance of epigenetic regulation for stem cell maintenance, cell polarity and adhesion in the regulation of asymmetric cell division of stem cells, and the activation of various signaling pathways and transcriptional programs for the correct differentiation of stem cell progeny.

In human cancer, invasion/metastasis is estimated to result in 90% of cancer morbidity [7]; and therefore, understanding the mechanisms that promote invasive/metastatic behaviour are of great importance clinically. The epithelial to mesenchymal transition (EMT) is a key event necessary for an epithelial cell to break adhesion with the other epithelial cells and to become migratory [50]. Changes in apico-basal cell polarity and cell morphology are central to this process [51,52,53]. In this special edition, Michael Murray describes the different *Drosophila* systems used to study EMT and cell invasion/metastasis and how this research has informed human cancer biology [30]. This review highlights the importance of cell polarity, cell adhesion, actin cytoskeletal regulators and signaling pathways in promoting EMT and invasive behaviour and reveals novel molecules that might provide new therapeutic opportunities for cancer therapy.

Finally in this review series, Stephen Gregory and colleagues cover the contribution of genomic instability, particularly chromosome instability (CIN), to tumorigenesis [32]. CIN is a hallmark of many human cancers, which is driven in part by loss of the DNA damage checkpoint tumor suppressor protein, p53, which is mutated in ~ 50% of all human cancer [7,54]. However, CIN is also triggered by mutation of other cell cycle checkpoint genes, such as those involved in the spindle assembly checkpoint, which is a surveillance mechanism ensuring correct connection of chromosome kinetochores to the mitotic spindle microtubules, that occurs before the metaphase to anaphase transition is initiated [55]. Disruptions to the centrosome (microtubule organizing center (MTOC)), required for correct spindle formation, is also linked to CIN [56]. Stephen Gregory and colleagues review various *Drosophila* systems used to study CIN in tumorigenesis and emphasise how *Drosophila* models are contributing to the discovery of new avenues to specifically target cancer cells that exhibit CIN to undergo cell death [32].

Overall this review series provides a snapshot of the power of the *Drosophila* model as a genetically amenable in vivo system to study the hallmarks of cancer and reveal novel genes that have therapeutic potential for human cancer. Not specifically covered in this review series are some of the emerging areas in the *Drosophila* and mammalian cancer research fields, that of cell metabolism and autophagy in cancer development [39,57-64], and epigenetic regulation of tumorigenesis, including chromatin remodeling and histone modification [65,66,67]. Furthermore, the use of *Drosophila* as a platform for anti-cancer drug discovery is an emerging area that is likely to make a major impact clinically [62,68-76]. Undoubtedly, these new areas, as well as further research into the topics covered in this review series, will provide further advances in the application of *Drosophila* models towards the understanding and treatment of human cancer.

## Acknowledgments

Thanks to Marta Portela for critical reading this manuscript. HER is supported by a Senior Research Fellowship from the National Health and Medical Research Council, Australia.

---

## Conflict of Interest

Author declares no conflicts of interest in this paper.

## References

1. Fortini ME, Skupski MP, Boguski MS, et al. (2000) A survey of human disease gene counterparts in the *Drosophila* genome. *J Cell Biol* 150: F23-30.
2. Cheng L, Parsons LM, Richardson HE (2013) Modelling cancer in *Drosophila* – The next generation. (version 2.0). *Encyclopedia Life Sciences (eLS Wiley)*. DOI: 10.1002/9780470015902.a0020862.pub2
3. Bier E (2005) *Drosophila*, the golden bug, emerges as a tool for human genetics. *Nat Rev Genet* 6: 9-23.
4. Gonzalez C (2013) *Drosophila melanogaster*: a model and a tool to investigate malignancy and identify new therapeutics. *Nat Rev Cancer* 13: 172-183.
5. Rudrapatna VA, Cagan RL, Das TK (2012) *Drosophila* cancer models. *Dev Dyn* 241: 107-118.
6. Brumby AM, Richardson HE (2005) Using *Drosophila melanogaster* to map human cancer pathways. *Nat Rev Cancer* 5: 626-639.
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144: 646-674.
8. Bangi E (2013) *Drosophila* at the intersection of infection, inflammation, and cancer. *Front Cell Infect Microbiol* 3: 103.
9. Pastor-Pareja JC, Xu T (2013) Dissecting social cell biology and tumors using *Drosophila* genetics. *Annu Rev Genet* 47: 51-74.
10. Stefanatos RK, Vidal M (2011) Tumor invasion and metastasis in *Drosophila*: a bold past, a bright future. *J Genet Genomics* 38: 431-438.
11. Tipping M, Perrimon N (2014) *Drosophila* as a model for context-dependent tumorigenesis. *J Cell Physiol* 229: 27-33.
12. Patel PH, Edgar BA (2014) Tissue design: how *Drosophila* tumors remodel their neighborhood. *Semin Cell Dev Biol* 28: 86-95.
13. Trosko JE (2014) Induction of iPS cells and of cancer stem cells: the stem cell or reprogramming hypothesis of cancer? *Anat Rec (Hoboken)* 297: 161-173.
14. Suh DH, Kim HS, Kim B, et al. (2014) Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. *Biochem Pharmacol* 92: 43-54.
15. Martin-Belmonte F, Perez-Moreno M (2012) Epithelial cell polarity, stem cells and cancer. *Nat Rev Cancer* 12: 23-38.
16. Januschke J, Gonzalez C (2008) *Drosophila* asymmetric division, polarity and cancer. *Oncogene* 27: 6994-7002.
17. Bell GP, Thompson BJ (2014) Colorectal cancer progression: lessons from *Drosophila*? *Semin Cell Dev Biol* 28: 70-77.
18. Janssens DH, Lee CY (2014) It takes two to tango, a dance between the cells of origin and cancer stem cells in the *Drosophila* larval brain. *Semin Cell Dev Biol* 28: 63-69.
19. Rosales-Nieves AE, Gonzalez-Reyes A (2014) Genetics and mechanisms of ovarian cancer: parallels between *Drosophila* and humans. *Semin Cell Dev Biol* 28: 104-109.
20. Spradling A, Fuller MT, Braun RE, et al. (2011) Germline stem cells. *Cold Spring Harb Perspect*

*Biol 3*: a002642.

21. Sousa-Nunes R, Somers WG (2013) Mechanisms of asymmetric progenitor divisions in the *Drosophila* central nervous system. *Adv Exp Med Biol* 786: 79-102.
22. Bausek N (2013) JAK-STAT signaling in stem cells and their niches in *Drosophila*. *JAKSTAT* 2: e25686.
23. Resende LP, Jones DL (2012) Local signaling within stem cell niches: insights from *Drosophila*. *Curr Opin Cell Biol* 24: 225-231.
24. Papagiannouli F, Lohmann I (2012) Shaping the niche: lessons from the *Drosophila* testis and other model systems. *Biotechnol J* 7: 723-736.
25. Lee JEA, Parsons LM, Quinn LM (2014) MYC function and regulation in flies: how *Drosophila* has enlightened MYC cancer biology. *AIMS Genet* 1: 81-98.
26. Ma X (2014) Context-dependent interplay between Hippo and JNK pathway in *Drosophila*. *AIMS Genet* 1: 20-33.
27. Estella C, Baonza A (2015) Cell proliferation control by Notch signaling during imaginal discs development in *Drosophila*. *AIMS Genet* 2: 70-96.
28. Frolidi F, Szuperak M, Cheng LY (2015) Neural stem cell derived tumorigenesis. *AIMS Genet* 2: 13-24.
29. La Marca JE, Somers WG (2014) The *Drosophila* gonads: models for stem cell proliferation, self-renewal and differentiation. *AIMS Genet* 1: 55-80.
30. Murray MJ (2015) *Drosophila* models of metastasis. *AIMS Genet* 2: 25-53.
31. Su TT (2015) Non-autonomous consequences of cell death and other perks of being metazoan. *AIMS Genet* 2: 54-69.
32. Liu D, Shaukat Z, Hussain R, et al. (2015) *Drosophila* as a model for chromosomal instability. *AIMS Genet* 2: 1-12.
33. Ntziachristos P, Lim JS, Sage J, et al. (2014) From fly wings to targeted cancer therapies: a centennial for notch signaling. *Cancer Cell* 25: 318-334.
34. Dominguez M (2014) Oncogenic programmes and Notch activity: an 'organized crime'? *Semin Cell Dev Biol* 28: 78-85.
35. Grusche FA, Degoutin JL, Richardson HE, et al. (2011) The Salvador/Warts/Hippo pathway controls regenerative tissue growth in *Drosophila melanogaster*. *Dev Biol* 350: 255-266.
36. Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. *Nat Rev Cancer* 13: 246-257.
37. Barron DA, Kagey JD (2014) The role of the Hippo pathway in human disease and tumorigenesis. *Clin Transl Med* 3: 25.
38. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat Rev Cancer* 9: 537-549.
39. Grifoni D, Bellosta P (2014) *Drosophila* Myc: A master regulator of cellular performance. *Biochim Biophys Acta* S1874-9399: 00188-6.
40. Quinn LM, Secombe J, Hime GR (2013) Myc in stem cell behaviour: insights from *Drosophila*. *Adv Exp Med Biol* 786: 269-285.
41. Johnston LA (2014) Socializing with MYC: cell competition in development and as a model for premalignant cancer. *Cold Spring Harb Perspect Med* 4: a014274.
42. Amoyel M, Bach EA (2014) Cell competition: how to eliminate your neighbours. *Development* 141: 988-1000.

43. Moreno E, Rhiner C (2014) Darwin's multicellularity: from neurotrophic theories and cell competition to fitness fingerprints. *Curr Opin Cell Biol* 31C: 16-22.
44. Ryoo HD, Bergmann A (2012) The role of apoptosis-induced proliferation for regeneration and cancer. *Cold Spring Harb Perspect Biol* 4: a008797.
45. Portela M, Richardson HE (2013) Death takes a holiday-non-apoptotic role for caspases in cell migration and invasion. *EMBO Rep* 14: 107-108.
46. Bissell MJ, Radisky D (2001) Putting tumours in context. *Nat Rev Cancer* 1: 46-54.
47. Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. *Annu Rev Cell Dev Biol* 22: 287-309.
48. Friedl P, Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. *Cell* 147: 992-1009.
49. Hogan C (2012) Impact of interactions between normal and transformed epithelial cells and the relevance to cancer. *Cell Mol Life Sci* 69: 203-213.
50. Hugo H, Ackland ML, Blick T, et al. (2007) Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. *J Cell Physiol* 213: 374-383.
51. Elsum I, Yates L, Humbert PO, et al. (2012) The Scribble-Dlg-Lgl polarity module in development and cancer: from flies to man. *Essays Biochem* 53: 141-168.
52. Godde NJ, Galea RC, Elsum IA, et al. (2010) Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. *J Mammary Gland Biol Neoplasia* 15: 149-168.
53. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer* 13: 97-110.
54. Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. *Nature* 481: 287-294.
55. Lee H (2014) How Chromosome Mis-Segregation Leads to Cancer: Lessons from Mouse Models. *Mol Cells* 37: 713-718.
56. Nam HJ, Naylor RM, van Deursen JM (2014) Centrosome dynamics as a source of chromosomal instability. *Trends Cell Biol* 25: 65-73.
57. Hirabayashi S, Baranski TJ, Cagan RL (2013) Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. *Cell* 154: 664-675.
58. Perez E, Das G, Bergmann A, et al. (2014) Autophagy regulates tissue overgrowth in a context-dependent manner. *Oncogene* [Epub ahead of print].
59. Mulakkal NC, Nagy P, Takats S, et al. (2014) Autophagy in Drosophila: from historical studies to current knowledge. *Biomed Res Int* 2014: 273473.
60. Ohsawa S, Sato Y, Enomoto M, et al. (2012) Mitochondrial defect drives non-autonomous tumour progression through Hippo signaling in Drosophila. *Nature* 490: 547-551.
61. Levayer R, Moreno E (2013) Mechanisms of cell competition: themes and variations. *J Cell Biol* 200: 689-698.
62. Willoughby LF, Schlosser T, Manning SA, et al. (2013) An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. *Dis Model Mech* 6: 521-529.
63. Nagy P, Varga A, Kovacs AL, et al. (2014) How and why to study autophagy in Drosophila: It's more than just a garbage chute. *Methods* [Epub ahead of print].
64. Strohecker AM, White E (2014) Targeting mitochondrial metabolism by inhibiting autophagy in

- BRAF-driven cancers. *Cancer Discov* 4: 766-772.
65. Das TK, Sangodkar J, Negre N, et al. (2013) Sin3a acts through a multi-gene module to regulate invasion in *Drosophila* and human tumors. *Oncogene* 32: 3184-3197.
  66. Kadamb R, Mittal S, Bansal N, et al. (2013) Sin3: insight into its transcription regulatory functions. *Eur J Cell Biol* 92: 237-246.
  67. Zhang C, Liu B, Li G, et al. (2011) Extra sex combs, chromatin, and cancer: exploring epigenetic regulation and tumorigenesis in *Drosophila*. *J Genet Genomics* 38: 453-460.
  68. Gladstone M, Su TT (2011) Chemical genetics and drug screening in *Drosophila* cancer models. *J Genet Genomics* 38: 497-504.
  69. Gladstone M, Frederick B, Zheng D, et al. (2012) A translation inhibitor identified in a *Drosophila* screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer. *Dis Model Mech* 5: 342-350.
  70. Markstein M, Dettorre S, Cho J, et al. (2014) Systematic screen of chemotherapeutics in *Drosophila* stem cell tumors. *Proc Natl Acad Sci U S A* 111: 4530-4535.
  71. Das TK, Cagan RL (2013) A *Drosophila* approach to thyroid cancer therapeutics. *Drug Discov Today Technol* 10: e65-71.
  72. Dar AC, Das TK, Shokat KM, et al. (2012) Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. *Nature* 486: 80-84.
  73. Jaklevic B, Uyetake L, Lemstra W, et al. (2006) Contribution of growth and cell cycle checkpoints to radiation survival in *Drosophila*. *Genetics* 174: 1963-1972.
  74. Edwards A, Gladstone M, Yoon P, et al. (2011) Combinatorial effect of maytansinol and radiation in *Drosophila* and human cancer cells. *Dis Model Mech* 4: 496-503.
  75. Gladstone M, Su TT (2011) Screening for radiation sensitizers of *Drosophila* checkpoint mutants. *Methods Mol Biol* 782: 105-117.
  76. Richardson HE, Willoughby L, Humbert PO (2015) Screening for anti-cancer drugs in *Drosophila*. *Encyclopedia Life Sciences (eLS Wiley)*. DOI: 10.1002/9780470015902.a0022535

© 2015, Helena E. Richardson, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)